Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure ...
A higher dose of Spinraza may be more effective than the currently approved dosing schedule for maintaining motor function in ...
Treatment with Spinraza (nusinersen) can help stabilize or improve motor function in adults with SMA, according to a new ...
Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.
Biogen licensed the global rights to develop, manufacture and commercialize SPINRAZA from Ionis Pharmaceuticals, Inc. (Nasdaq: IONS). Please click here for Important Safety Information and ...
Biogen BIIB reported fourth-quarter 2024 adjusted ... Sales of spinal muscular atrophy (SMA) drug, Spinraza, improved slightly in the quarter. Sales beat the Zacks Consensus Estimate of $2.42 ...
Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback